The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Infinity Expands Executive Leadership Team, Appointing David A. Roth as Senior Vice President, Clinical Development and Medical Affairs

Wednesday, September 04, 2013

Infinity Expands Executive Leadership Team, Appointing David A. Roth as Senior Vice President, Clinical Development and Medical Affairs

08:30 EDT Wednesday, September 04, 2013

CAMBRIDGE, Mass. (Business Wire) -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the appointment of David A. Roth, M.D., as senior vice president, clinical development and medical affairs. In this newly created role, Dr. Roth will have responsibility for the clinical development organization and clinical operations, and he will also build and oversee the medical affairs function. Dr. Roth will serve as a member of Infinity's executive leadership team and will report to Pedro Santabarbara, M.D., Ph.D., the company's chief medical officer. Dr. Roth brings to Infinity over 20 years of experience in hematology and oncology research and development.

“It's a pleasure to welcome David to Infinity. He holds a distinguished track record spanning both industry and academia. His appointment substantially enhances the depth and breadth of Infinity's hematology and oncology expertise as we rapidly advance our lead program, IPI-145, toward late-stage development and potential registration,” stated Dr. Santabarbara. “David's experience encompasses both early-stage and registration-phase programs, and the Infinity team looks forward to his contributions as we work to advance and expand our pipeline.”

“Infinity's PI3K-delta,gamma inhibitor, IPI-145, has the potential to help transform the treatment landscape for patients with hematologic malignancies, and I am pleased to join Infinity at such an exciting time,” commented Dr. Roth. “Infinity has a history grounded in science and academic collaborations, and I'm delighted to be a part of this team as we strive to bring important new treatment options to patients and their physicians.”

Dr. Roth joins Infinity following more than ten years with Pfizer Inc. and Wyeth Pharmaceuticals. At Pfizer, he most recently served as a vice president in Pfizer's oncology business unit. Dr. Roth joined Pfizer from Wyeth, where he held the role of assistant vice president, clinical research & development and global therapeutic area director of hematology. While at Pfizer and Wyeth, Dr. Roth contributed to the successful regulatory approval of several products, including Bosulif® (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, Xyntha® and ReFacto AF® for the treatment of hemophilia A, and BeneFIX® for the treatment of hemophilia B. Dr. Roth also led the early development of palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER positive advanced breast cancer. During his tenure at Pfizer and Wyeth, Dr. Roth also co-chaired Pfizer's oncology research and development board and served on several oncology and hematology R&D leadership teams and governance committees.

In addition to his extensive industry experience, Dr. Roth is an accomplished academic researcher and clinical practitioner. He received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology where he remains on the Affiliated Faculty.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's programs focused on the inhibition of phosphoinositide-3-kinase and heat shock protein 90 are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company's website at www.infi.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the company's expectations about: the expected responsibilities of Dr. Roth; the advancement of IPI-145 toward late-stage development and potential registration; and the therapeutic potential of its PI3K inhibitors. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that Infinity will initiate clinical trials or report data in the time frames it has estimated, that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Infinity's product candidates will continue. Further, there can be no guarantee that any positive developments in Infinity's product portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Infinity's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Infinity's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of agents by Infinity's competitors for diseases in which Infinity is currently developing its product candidates; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption “Risk Factors” included in Infinity's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2013, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Bosulif® and Xyntha® are registered trademarks of Wyeth LLC. ReFacto AF® and BeneFIX® are registered trademarks of Genetics Institute, LLC.

Infinity Pharmaceuticals, Inc.
Jaren Irene Madden, 617-453-1336
Jaren.Madden@infi.com
http://www.infi.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections